癌基因蛋白质类

摘要： 目的 探讨Aptima HPV检测(是基于HPV E6、E7 mRNA检测的方法)联合Aptima HPV 16型和HPV 18型和(或)45型(18/45型)分型(Aptima HPV-GT)检测作为子宫颈癌机会性筛查方法的可行性.方法 收集2016年10月—2017年10月在浙江省湖州市妇幼保健院体检或因妇科疾病就诊并自愿接受Aptima HPV检测(对其中HPV阳性妇女进一步行Aptima HPV-GT检测)和液基薄层细胞学检查(TCT)的妇女共23 258例,其年龄为(40±9)岁.对Aptima HPV检测阳性或TCT检查结果为低级别鳞状上皮内病变(LSIL)及以上病变或临床症状明显(如性交后出血、血性分泌物)的妇女行阴道镜检查,必要时在阴道镜定位下行子宫颈活检±子宫颈管搔刮(ECC)术.(1)分别比较不同细胞学诊断和组织学诊断妇女的Aptima HPV及Aptima HPV-GT检测结果.(2)以组织学诊断为"金标准",比较Aptima HPV检测与TCT检查对组织学诊断≥高级别鳞状上皮内病变(HSIL;包括HSIL、原位腺癌、腺癌、鳞癌和腺鳞癌)的筛查价值.结果(1)23 258例妇女中,Aptima HPV、HPV 16型和HPV 18/45型阳性率分别为14.00%(3 257/23 258)、1.85%(430/23 258)和0.86%(199/23 258).在细胞学诊断为未见上皮内病变或恶性病变(NILM)、未明确诊断意义的不典型鳞状上皮细胞(ASCUS)、LSIL、不能除外高度病变的不典型鳞状上皮细胞(ASC-H)、HSIL和鳞癌的妇女中,Aptima HPV、HPV 16型和HPV 18/45型阳性率均随着细胞学诊断的病变级别的增高而明显增高(P均=0.000);在组织学诊断为正常子宫颈、LSIL、HSIL、鳞癌的妇女中,Aptima HPV、HPV 16型和HPV 18/45型阳性率也均随着组织学诊断的病变级别的增高而明显增高(P均=0.000).在组织学诊断≥HSIL病变中,Aptima HPV检测阳性率为98.11%(311/317),明显高于组织学诊断≤LSIL者[包括正常子宫颈及LSIL,为12.84%(2 946/22 941);P=0.000];Aptima HPV-GT检测阳性率为58.36%(185/317),明显高于组织学诊断≤LSIL者[1.91% (439/22 941);P=0.000].(2)以组织学诊断为"金标准",在筛查组织学诊断≥HSIL的病变时,Aptima HPV检测的敏感度(分别为98.11%、59.62%)和阴性预测值(分别为99.97%、99.42%)均显著高于细胞学TCT检查(P均=0.000),但其特异度(分别为87.16%、95.37%)和阳性预测值(分别为9.55%、15.10%)则显著低于细胞学TCT检查(P均=0.000).结论 Aptima HPV检测阳性特别是Aptima HPV-GT检测阳性的妇女发生组织学诊断≥HSIL病变的可能性大.在有条件的医院,Aptima HPV联合Aptima HPV-GT检测作为子宫颈癌机会性筛查方法是可行的.%Objective To evaluate Aptima HPV E6 and E7 mRNA assay (Aptima HPV) combined with Aptima HPV 16 and 18 or 45 (18/45) genotype assay (Aptima HPV-GT) as a means of cervical cancer opportunistic screening. Methods From October 2016 to October 2017, a total of 23 258 women aged 25-65 years were enrolled in the physical examination center and gynecological clinic of Huzhou Maternity and Child Health Care Hospital. All the women had Aptima HPV tested, further Aptima HPV-GT testing for positive women and liquid-based thin layer cytology Thinprep cytologic test (TCT). Women with Aptima HPV (+) or ≥low-grade squamous intraepithelial lesion (LSIL) or obvious clinical symptoms (including vaginal bleeding after intercourse and watery, bloody vaginal discharge) were referred for colposcopy and further biopsy with or without endocervical curettage (ECC) if indicated. Expression of Aptima HPV, HPV 16 and HPV 18/45 with different cytological diagnostic groups and histological diagnosis groups were compared respectively. Sensitivity, specificity, positive predictive value and negative predictive value of Aptima HPV detection and TCT in identifying histological diagnosis of high-grade squamous intraepithelial lesion (HSIL) or worse (HSIL+) were compared. Results (1) The positive rates of Aptima HPV, HPV 16 and HPV 18/45 were 14.00% (3 257/23 258), 1.85% (430/23 258) and 0.86% (199/23 258) respectively.The positive rates of Aptima HPV, HPV 16 and HPV 18/45 increased with cytology grading in squamous epithelium [negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASCUS), LSIL, atypical squamous cell cannot exclude HSIL (ASC-H), HSIL and squamous cell carcinoma (SCC), all P=0.000)]. According to histology results, the positive rates of Aptima HPV, HPV 16 and HPV 18/45 increased with histology grading in squamous epithelium (normal cervical tissue, LSIL, HSIL and SCC, all P=0.000). The positive rate of Aptima HPV was significantly higher in HSIL+group than that in the LSIL or better (LSIL-) group [98.11% (311/317) vs 12.84% (2 946/22 941), P=0.000]. The positive rate of Aptima HPV-GT was significantly higher in HSIL+group than that in LSIL-group [58.36% (185/317) vs 1.91% (439/22 941), P=0.000]. (2) Compared with cytology, Aptima HPV resulted in significant higher sensitivity (98.11% vs 59.62%, P=0.000) and negative predictive value (99.97% vs 99.42%, P=0.000), significant lower specificity (87.16% vs 95.37%, P=0.000) and positive predictive value (9.55% vs 15.10%, P=0.000) when identified HSIL+. Conclusions Women with Aptima HPV positive, especially those with Aptima HPV-GT positive, are more likely to have histological diagnosis of HSIL+. Aptima HPV combined with Aptima HPV-GT is feasible as a means of cervical cancer opportunistic screening in tertiary hospitals.

摘要： Objective:To measure the expression levels of HOXA 11 mRNA and protein in endometrial tissues of patients after radical trachelectomy (RT),and to investigate the effect of HOXA11 on endometrial receptivity.Methods:There were two groups in this study.The RT group included 16 infertile patients after RT treatment.Another group included 16 fertile patients after RT as control.The endometrial tissue was biopsied with the informed consent.The expression of HOXA 11 mRNA in endometrial tissue was detected by real-time RT-PCR.The expression levels of HOXA11,Integrin-β3,β-catenin and DKK1 proteins were measured by Western blots.Results:The expression of HOXA 11 mRNA in the RT infertile group was significantly lower than that in the control group (P＜0.05).The expression levels of HOXA11,Integrin-β3,β-catenin and DKK1 proteins in the RT infertile group were significantly lower than those in the control group (all P＜0.05).Interestingly,the expression level of HOXA11 was positively correlated with the expression level of Intergin-β3,β-catenin or DKK1,respectively (P values were 0.006,0.004 and 0.007).Conclusions:The expression of HOXA 11 in endometrial tissue was significantly decreased in those infertile patients after RT,which down regulated the expression of integrin-β3 and the Wnt/β-catenin pathway related with endometrial receptivity.This is one of the possible mechanisms of the failed embryo implantation and infertile outcome.%目的:探讨根治性宫颈切除术(radical trachelectomy,RT)患者术后同源盒基因A11(HOXA 11)的表达对子宫内膜容受性的影响.方法:应用实时聚合酶链反应(real-time PCR)检测RT术后不孕症患者(n=16)与正常生育能力女性(n=16)分泌期子宫内膜组织中HOXA 11基因的mRNA表达水平,并应用蛋白质印迹法(Western blotting)分别检测2组患者分泌期子宫内膜组织中HOXA11、整合素β3(Integrin-β3)以及β-catenin、Dickkopf-1(DKK1)蛋白的表达水平.结果HOXA11基因在RT组和对照组的分泌期子宫内膜中均有表达,但RT组低于对照组,差异有统计学意义(P＜ 0.05);HOXA11、Integrin-β3以及β-catenin、DKK1蛋白在RT组的表达也低于对照组,差异有统计学意义(P＜0.05).且HOXA11与Intergin-β3蛋白、β-catenin蛋白及DKK1蛋白的表达强度均呈显著正相关(盼别为0.006、0.004和0.007).结论:在RT术后不孕可能由于宫颈组织的缺失从而影响宫腔内HOXA 11基因的正常表达,并相应调节Integrin-β3及Wnt/β-catenin通路的表达,从而干扰子宫内膜容受性的形成,导致胚胎着床失败而不孕.

摘要： 目的:提取中药黄芪的有效成分黄芪多糖,观察其对人免疫重建荷子宫内膜癌SCID小鼠血清中性粒细胞明胶酶相关脂质运载蛋白(neutrophil gelatinase-associated lipocalin,NGAL)及其受体NGALR表达的影响.方法:将36只雌性CB-17 SCID小鼠,分为空白对照组、荷瘤组和治疗组,每组各12只.荷瘤组和治疗组先经腹腔注射5×107个/mL人淋巴细胞分离液(PBMC),后肢内侧皮下接种3×106个/mL子宫内膜腺癌细胞株(HEC-1B)建立人免疫重建荷子宫内膜癌模型.成瘤后治疗组按20 mg/kg剂量肌内注射黄芪多糖治疗10 d,空白对照组和荷瘤组注射等量生理盐水.酶联免疫吸附法(ELISA)测定血清NGAL及NGALR蛋白表达,逆转录聚合酶链反应(RT-PCR)检测荷瘤鼠肿瘤组织中NGAL和NGALR基因表达,测量荷瘤组和治疗组小鼠瘤体积、瘤质量并计算肿瘤抑制率.结果:治疗组治疗后与荷瘤组和同组治疗前比较NGAL及NGALR蛋白表达均减弱,NGAL mRNA及NGALR mRNA均低表达,瘤体积和瘤质量均明显降低,抑瘤率提高,差异均有统计学意义(均P<0.05).结论:黄芪多糖可能通过抑制NGAL及NGALR蛋白及其基因的表达而发挥抗肿瘤作用.%Objective:To extract the active ingredients of Astragalus astragalus polysaccharide, observe the immune reconstruction load in endometrial carcinoma SCID mice serum neutrophil gelatinase associated lipocalin (neutrophil gelatinase-associated lipocalin, NGAL) and its receptor NGALR expression influence. Methods:36 female CB-17 SCID mice were divided into blank control group, tumor group and treatment group, tumor group and treatment group were intraperitoneal injection of 5×107/mL Lymphocytes Separation Medium (PBMC), lymphocyte suspension hind leg subcutaneously with 3×106/mL endometrial adenocarcinoma cell line (HEC-1B) establishment of human immune reconstitution in endometrial cancer bearing model. After treatment, the treatment group was injected with astragalus polysaccharide at 20 mg/kg dose for 10 days (d), and the normal control group and the tumor bearing group were injected with normal saline. Enzyme linked immunosorbent assay (ELISA) expression of serum NGAL and NGALR protein were determined by reverse transcriptase polymerase chain reaction (RT-PCR) expression of NGAL gene and NGALR gene detection of tumor tissue, measuring tumor group and treatment group tumor volume, tumor weight and tumor inhibition rate was calculated. Results:After treatment, the treatment group of NGAL and NGALR protein expression decreased, NGAL mRNA and NGALR mRNA were low expression, tumor volume and tumor weight were significantly decreased, the inhibition rate increased, compared with the tumor bearing group and the same group before treatment, the differences were statistically significant (P<0.05). Conclusions:Astragalus polysaccharides may exert antitumor effects by inhibiting the expression of NGAL and NGALR proteins and their genes.

摘要： FOXJ1是叉头框蛋白家族中的一员,其与乳腺癌、卵巢癌、子宫内膜癌、胃癌以及室管膜和脉络丛肿瘤的恶性程度及预后均有密切关系.本文对FOXJ1的结构与功能及其与疾病的相关性进行系统阐述,为肿瘤的早期诊断、预测和治疗提供新的思路.

摘要： 约25％～30％的非小细胞肺癌为鳞癌。肺鳞癌的治疗可选性相对较小。在晚期肺鳞癌治疗中，培美曲塞单药和联合治疗未被批准‘引，血管内皮生长因子受体抑制剂贝伐珠单抗（bevacizumab）因易伴随出血事件而被禁用。

摘要： Objective To explore the relationship between wild type RET (WT-RET)and RET/PTC fusion gene expression and the development of papillary thyroid carcinoma(PTC).Methods 35 cases of fresh PTC tissues,the corresponding paracancerous thyroid tissues and 10 cases of fresh adjacent benign thyroid lesions normal tissues were collected.Expression of RET/PTC 1,2 and 3 fusion gene were detected by Nested PCR and DNA sequence test.Expression of WT-RET and RET tyrosine kinase (RET-TK)mRNA were detected by quantitative Real Time PCR.RET mRNA expression in the source was detected by in situ hybridization.Results Among the 35 cases of PTC,17 cases had positive RET/PTC fusion gene(15 cases of positive RET/PTC 1,0 case of positive RET/PTC 2 was,2 cases of positive RET/PTC 3),and all positive cases were confirmed by DNA sequence test.Almost no expression of WT-RET and RET-TK mRNA was found in paracancerous thyroid tissues,while their expressions in RET/PTC negative group were 2 times higher than those in the respective paracancerous thyroid tissues (P＜0.01,P＜0.01)and their expression in RET/PTC positive group was 3 times and 64 times higher than the respective paracancerous thyroid tissues (P＜0.01,P＜0.01).Expression of WT-RET mRNA had no statistical difference between RET/PTC positive group and negative group (P＞0.05).Expression of RET-TK mRNA in RET/PTC positive group was significantly higher than that in the negative group,and the difference has statistical significance (P＜0.01).In situ hybridization showed RET mRNA expressed in the cell membrane and cytoplasm.Expression of RET/PTC fusion gene was not statistically correlated with clinical parameters such as age,gender,tumor size,lymph node metastasis or clinical stage(P＞0.05).Conclusions ①Expression ratio of RET/PTC positive is not high in sporadic PTC in Anhui province,and its diagnostic and prognosis significance is limited.②Expression of WTRET in follicular cells in sporadic PTC may promote the occurance of RET/PTC fusion gene,and the two may commonly involved in the occurrence of thyroid tumor.%目的 探讨野生型RET(wild type RET,WT-RET)和RET/PTC融合基因的表达与安徽地区人群PTC发生、发展的关系.方法 收集新鲜的35例PTC和相应的35例癌旁组织及10例甲状腺良性病变旁正常组织,巢氏PCR检测RET/PTC 1、2和3的表达,DNA测序检测融合基因序列.实时荧光定量PCR检测WT-RET和RET酪氨酸激酶区(RET tyrosine kinase,RET-TK)mRNA表达水平.原位杂交法检测RET的表达位置.结果 35例PTC中,RET/PTC阳性组织17例,其中RET/PTC1阳性15例,RET/PTC2阳性0例,RET/PTC3阳性2例,并运用DNA测序证实.WT-RET与RET-TK 2者在癌旁组织都几乎不表达,2者在RET/PTC阴性组的表达都是各自癌旁组织的2倍(P＜0.01,P＜0.01),2者在RET/PTC阳性组的表达分别是各自癌旁组织的3倍(P＜0.01)和64倍(P＜0.01).WT-RET在RET/PTC阳性与阴性2组之间表达差异无统计学意义(P＞0.05),RET-TK在RET/PTC阳性组表达明显高于阴性组,差异有统计学意义(P＜0.01).原位杂交结果显示RET表达于PTC滤泡细胞膜和细胞浆.RET/PTC与PTC临床参数如性别、年龄、肿瘤直径、淋巴结转移及临床分期等均差异无统计学意义(P＞0.05).结论 ①安徽地区人群散发性PTC中RET/PTC表达率不高,其对PTC的诊断和判断预后的价值不大.②散发性PTC中滤泡细胞表达WT-RET,可能促进了RET/PTC的发生,并共同参与了甲状腺肿瘤的发生.

摘要： 目的：评估中性粒细胞明胶酶相关性脂质运载蛋白（NGAL）在健康成年人中的参考值范围。方法采用丹麦Bio-porto公司试剂盒，用胶乳增强免疫比浊法在日立全自动生化分析仪上测定252例健康成年体检者血清NGAL 浓度并进行统计学分析，建立NGAL参考值范围。同时分别测量同型半胱氨酸（Hcy）、半胱氨酸抑制酶 C（CysC）、β2微球蛋白（β2-MG）水平，分析年龄、性别及所测肾功能各项参数与NGAL的相关性。结果 NGAL 在健康人群中呈近似正态分布。17～＜50岁的NGAL水平与50～＜90岁比较差异有统计学意义（P＜0．05）。NGAL 与年龄的相关性最为密切（狉＝0．268，P＜0．01），其次是β2-MG （狉＝0．180，P＜0．01）。此外，CysC也与NGAL有一定的相关性（狉＝0．137，P＜0．05）。以50岁为分界年龄，以97．5％为参考值上限，健康成年人不同年龄的NGAL参考值范围是：17～＜50岁NGAL ＜73．94 ng/mL，50～＜90岁NGAL＜87．85 ng/mL。结论年龄及其他生理指标可以影响健康者NGAL分布，仪器、试剂及所检测标本的不同也会使所测NGAL 范围不一致，因此各实验室需建立自己的NGAL参考值范围。

摘要： Objective To evaluate the prevalence of the DJ-1 mutation in early-onset Parkinson's disease (EOPD) patients,and analyzed the association between the certain polymorphic marker g.168_185del in intron1 and Parkinson' s disease (PD).Methods We screened all 7 exons and exon-intron boundary regions of DJ-1 by PCR and direct nucleotide sequencing in 90 Chinese patients with EOPD.We also compared the allele and genotype frequencies of the g.168_185del polymorphism between EOPD patients and controls.Results We found no causative DJ-1 mutations in our cohort of Chinese EOPD patients.But we did identified 4 known polymorphic variants,including the g.168_185del in intron 1,g.5027G ＞ A (rs17523802),g.5065T ＞ C (rs226249),and g.5094C ＞ T (rs11121064) within exon 1.Del/Ins frequencies of the g.168_185 del polymorphism were 11.1％ (10/90)and 13.3％ (14/105) in EOPD group and normal group,respectively.Ins/Ins frequencies were 88.9％ (80/90) and 86.7％ (91/105),thex2 and P value of genotype frequency were 0.222 and 0.669 between EOPD patients and controls,respectively.The insert frequencies were 94.4％ (170/180)and 93.3％ (196/210) in EOPD patients and controls,the deletion frequencies were 5.6％ (10/180) and 6.7％ (14/210),thex2 and P value of allele frequency were 0.207 and 0.679 between EOPD patients and normal,respectively.Furthermore,the P value of genotype and allele frequencies were 0.736 and 0.744 between familial EOPD patients and controls,respectively;P values of genotype and allele frequencies were 0.847 and 0.852 between sporadic EOPD patients and control group,respectively.There was no statistical difference between groups.Conclusion Mutations in DJ-1 are uncommon in Chinese EOPD patients,and no association is observed between the DJ-1 intron 1 g.168_185del polymorphism and risk of PD.%目的 探讨在早发型帕金森病患者(early-onset Parkinson's disease,EOPD)中DJ-1基因的突变情况,并分析1号内含子上g.168_185del多态类型是否与帕金森病的发生有关.方法 应用聚合酶链反应(PCR)结合直接测序法对90例EOPD患者进行DJ-1基因7个外显子突变分析.针对1号内含子的g.168_185del多态性,比较EOPD患者与健康人的基因型频率及等位基因频率是否存在差异.结果 (1)在90例EOPD患者中没有筛查出DJ-1基因的致病性突变,但发现位于1号外显子上g.5027G＞A(rs17523802)、g.5065T＞C(rs226249)、g.5094C ＞T (rs11121064)及位于1号内含子的g.168 185del 4种多态类型.(2)针对g.168_185del分析,EOPD组与健康对照组插入/缺失频率分别为11.1％ (10/90)和13.3％(14/105),插入/插入频率分别为88.9％(80/90)和86.7％(91/105),比较基因型频率x2值为0.222,P值为0.669；EOPD组与对照组插入型频率分别为94.4％(170/180)和93.3％ (196/210),缺失型频率分别为5.6％ (10/180)和6.7％ (14/210),比较等位基因频率x2值为0.207,P值为0.679；家族性EOPD组与对照组间基因型频率及等位基因频率,散发性EOPD组与对照组间基因型频率及等位基因频率差异均无统计学意义.结论 本组EOPD患者中DJ-1基因的突变率较低,不是常见致病因素；g.168_185del多态位点与EOPD患者可能无直接致病关系.

摘要： 本发明的课题是提供通过确定与除虫菊酯的生物合成相关的酶的氨基酸序列、及其基因的碱基序列，制作整合有该基因的载体、转化体，并将这些制作技术应用于生长较快的植物，从而高效地生成除虫菊酯的方法。本发明提供一种基因，是编码作为可以从能生成除虫菊酯的植物体内提取的酶的下述(i)或(ii)的蛋白质的基因，(i)包含序列号1所示的氨基酸序列的蛋白质，(ii)包含对序列号1所示的氨基酸序列置换、缺失、插入、和/或添加1个或多个氨基酸而得到的氨基酸序列、且显示作为除虫菊酯生物合成酶的活性的蛋白质。

摘要： 由具有糖蛋白生成抑制活性的序列表中序列1记载的氨基酸序列构成的蛋白质、其变异体蛋白质、由序列表中序列2记载的核苷酸序列组成的DNA、其DNA变异体以及使用上述蛋白质和DNA的糖蛋白异常症(例如囊性纤维化症)的包括基因治疗在内的治疗药。

摘要： 本发明提供了一种通过突变HMGR的特定氨基酸残基获得的突变的蛋白质，其为类萜生物合成通路中异戊二烯单体生物合成的限速酶。本发明涉及一种突变的蛋白质，其中在3‑羟基‑3‑甲基戊二酰‑辅酶A还原酶中，选自于由SEQ ID NO：1所示的拟南芥3‑羟基‑3‑甲基戊二酰‑辅酶A还原酶的第91位、225位、257位、287位、339位、411位、470位、509位和574位氨基酸残基、以及位置与前述相当的氨基酸残基构成的组的至少一种氨基酸残基被缺失，或被其它氨基酸残基取代。

摘要： 由下述氟树脂形成了与蛋白质或包含蛋白质的组合物接触的表面的容器及用于制造蛋白质或包含蛋白质的组合物的器材具有显著的低蛋白质吸附性，其中，所述氟树脂为选自四氟乙烯‑六氟丙烯系共聚物及四氟乙烯‑全氟烷基乙烯基醚系共聚物中的至少1种氟树脂，并且，所述氟树脂的熔点为320°C以下，所述氟树脂中的相对于每1×10

摘要： 本发明提供能减小使用了特异性地结合的物质的测定中的由肝型脂肪酸结合蛋白质引起的测定值的变动幅度的肝型脂肪酸结合蛋白质制剂、评价该制剂的方法、制作肝型脂肪酸结合蛋白质的校准曲线的方法、以及定量该蛋白质的方法。一种用使用了用10mM的氧化剂在25°C下进行1小时的氧化处理的肝型脂肪酸结合蛋白质制剂的测定值与使用了未进行上述氧化处理的肝型脂肪酸结合蛋白质制剂的测定值的比表示的氧化变动系数设定为1.4以下的肝型脂肪酸结合蛋白质制剂、用于该制剂的肝型脂肪酸结合蛋白质、编码该蛋白质的DNA、由该DNA转化得到的细胞、该蛋白质的制造方法、评价该制剂的方法、抑制使用该制剂的测定中的测定值的变动幅度的方法、制作该蛋白质的校准曲线的方法、以及定量该蛋白质的方法。

摘要： 本发明提供一类能够携带生物活性蛋白分子穿透细胞膜的非肽类多胍有机小分子或其药学上可接受的盐，所述非肽类多胍有机小分子具有式I所示的结构：

摘要： 本发明的课题是提供通过确定与除虫菊酯的生物合成相关的酶的氨基酸序列、及其基因的碱基序列，制作整合有该基因的载体、转化体，并将这些制作技术应用于生长较快的植物，从而高效地生成除虫菊酯的方法。本发明提供一种基因，是编码作为可以从能生成除虫菊酯的植物体内提取的酶的下述(i)或(ii)的蛋白质的基因，(i)包含序列号1所示的氨基酸序列的蛋白质，(ii)包含对序列号1所示的氨基酸序列置换、缺失、插入、和/或添加1个或多个氨基酸而得到的氨基酸序列、且显示作为除虫菊酯生物合成酶的活性的蛋白质。

摘要： 本发明涉及一种类钙调磷酸酶B亚基蛋白基因及其编码蛋白质和该基因的克隆，所述的类钙调磷酸酶B亚基蛋白基因源于蔷薇科植物，类钙调磷酸酶B亚基蛋白基因为SEQ ID NO：1或SEQ ID NO：2，其编码蛋白质为SEQ ID NO：3；所述的类钙调磷酸酶B亚基蛋白基因可以通过设计的引物予以克隆；类钙调磷酸酶B亚基蛋白基因可以通过提高自身的表达水平来增强植物对生物和非生物胁迫的防御能力，对于该科植物的抗逆境分子生物学研究具有重要现实意义。

摘要： 本发明公开了人抑癌基因、由其编码的蛋白质、包含该基因的表达载体以及用该载体转化的微生物。本发明的抑癌基因可以有效地用于诊断、预防和治疗人类癌症。

摘要： 本发明披露了一种新的原癌基因和该原癌基因编码的蛋白质。本发明的原癌基因可有效地用于诊断包括乳腺癌、白血病、子宫癌、恶性淋巴瘤等的多种癌症。